Practical considerations of single-fraction stereotactic ablative radiotherapy to the lung
- Author(s)
- Kang, TMJ; Hardcastle, N; Singh, AK; Slotman, BJ; Videtic, GMM; Stephans, KL; Counago, F; Louie, AV; Guckenberger, M; Harden, SV; Plumridge, NM; Siva, S;
- Journal Title
- Lung Cancer
- Publication Type
- Review
- Abstract
- Stereotactic ablative radiotherapy (SABR) is a well-established treatment for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC) and pulmonary oligometastases. The use of single-fraction SABR in this setting is supported by excellent local control and safety profiles which appear equivalent to multi-fraction SABR based on the available data. The resource efficiency and reduction in hospital outpatient visits associated with single-fraction SABR have been particularly advantageous during the COVID-19 pandemic. Despite the increased interest, single-fraction SABR in subgroups of patients remains controversial, including those with centrally located tumours, synchronous targets, proximity to dose-limiting organs at risk, and concomitant severe respiratory illness. This review provides an overview of the published randomised evidence evaluating single-fraction SABR in primary lung cancer and pulmonary oligometastases, the common clinical challenges faced, immunogenic effect of SABR, as well as technical and cost-utility considerations.
- Keywords
- *COVID-19/epidemiology; *Carcinoma, Non-Small-Cell Lung/pathology; Humans; Lung/pathology; *Lung Neoplasms/pathology; Pandemics; *Radiosurgery/adverse effects; *Small Cell Lung Carcinoma; Lung cancer; Lung oligometastases; Nsclc; Radiation therapy; Sabr; Single fraction
- Department(s)
- Radiation Oncology; Physical Sciences
- PubMed ID
- 35843149
- Publisher's Version
- https://doi.org/10.1016/j.lungcan.2022.06.014
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-12-19 03:18:24
Last Modified: 2024-12-19 03:23:08